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Abstract
Background: Acute coronary syndromes, including myocardial infarction and unstable angina, are important
causes of premature mortality, morbidity and hospital admissions. Acute coronary syndromes consume large
amounts of health care resources, and have a major negative economic and social impact through days lost at
work, support for disability, and coping with the psychological consequences of illness. Several registries have
shown that evidence based treatments are under-utilised in this patient population, particularly in high-risk
patients. There is evidence that systematic educational programmes can lead to improvement in the management
of these patients. Since application of the results of important clinical trials and expert clinical guidelines into
clinical practice leads to improved patient care and outcomes, we propose to test a quality improvement
programme in a general group of hospitals in Europe.
Methods/Design: This will be a multi-centre cluster-randomised study in 5 European countries: France, Spain,
Poland, Italy and the UK. Thirty eight hospitals will be randomised to receive a quality improvement programme or
no quality improvement programme. Centres will enter data for all eligible non-ST segment elevation acute
coronary syndrome patients admitted to their hospital for a period of approximately 10 months onto the study
database and the sample size is estimated at 2,000-4,000 patients. The primary outcome is a composite of eight
measures to assess aggregate potential for improvement in the management and treatment of this patient
population (risk stratification, early coronary angiography, anticoagulation, beta-blockers, statins, ACE-inhibitors,
clopidogrel as a loading dose and at discharge). After the quality improvement programme, each of the eight
measures will be compared between the two groups, correcting for cluster effect.
Discussion: If we can demonstrate important improvements in the quality of patient care as a result of a quality
improvement programme, this could lead to a greater acceptance that such programmes should be incorporated
into routine health training for health professionals and hospital managers.
Trial registration: Clinicaltrials.gov NCT00716430
* Correspondence: m.flather@rbht.nhs.uk
1Clinical Trials and Evaluation Unit, Royal Brompton Hospital, Sydney Street,
SW7 6NP, UK
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Background
Acute coronary syndromes (ACS), including myocardial
infarction and unstable angina, are important causes of
premature mortality, morbidity and hospital admissions
in Europe and worldwide [1,2]. ACS consumes large
amounts of health care resources, and has a major nega-
tive economic and social impact through days lost at
work, support for disability, and coping with the psycho-
logical consequences of illness. Given this large health
burden it is vital to implement the best cost-effective
treatments for ACS.
ACS is usually classified based on the ECG at presen-
tation. Those with persistent ST elevation require an
urgent reperfusion strategy with thrombolysis or pri-
mary angioplasty, and those without persistent ST-eleva-
tion (also called “non-ST elevation”) ACS require early
risk assessment, intensive medical treatment (including
anti-thrombotic and anti-ischaemic drugs), and early
revascularisation if clinically indicated. This proposal
will focus on the management of patients with non-ST
elevation ACS.
The management of patients has to be tailored to
individual needs and the availability of resources but it
is widely accepted that patients with ACS need high
standards of early care as this has a major impact on
short and long-term prognosis. Treatments such as
aspirin, beta-blockers, heparin and statins should be
given routinely to a wide range of patients and for many
others clopidogrel and ACE inhibitors are also needed.
In addition, invasive procedures such as coronary angio-
graphy and revascularisation are becoming more com-
mon in an attempt to treat the underlying lesions that
may cause ongoing ischaemia and trigger future events
[3,4].
Several large registries have shown that there are defi-
ciencies in the treatment of non-ST elevation acute cor-
onary syndromes when compared to recommendations
from contemporary guidelines [5-17]. Under-utilisation
of evidence-based treatments such as beta-blockers,
heparin, statins and ACE inhibitors is common. Recent
guidelines recommend targeting more intense treatment
to higher risk groups [3,18] but evidence from the regis-
tries indicates that, paradoxically, these patients, and
particularly subsets of them such as the elderly, diabetics
and those with heart failure, often receive less intensive
treatment than that recommended [15,17,19,20]. Guide-
lines also emphasise more intense investigation and
treatment including early angiography (within 72 hrs of
admission), the use of upstream glycoprotein IIb/IIIa
(GP IIb/IIIa) inhibitors and revascularisation, as indi-
cated, especially in higher risk patients. However, the
registries again suggest that this strategy is not necessa-
rily targeted at the high-risk patients.
Several models to determine the risk of death, or the
composite of death or myocardial infarction (MI) during
the in-hospital period and over the ensuing months,
have been developed. Some have used data from clinical
trials (TIMI, GUSTO, PURSUIT) [21-23] while others
have used observational data (NRMI, GRACE) [24,25].
The TIMI and GRACE models [21,25,26] provide a
scoring system in which an increased score denotes
higher risk and this increases their potential to be used
in the routine clinical setting. The ESC guidelines pro-
vide a more pragmatic guide by listing features com-
monly found in high-risk patients, without providing a
detailed method of determining risk [3,18].
Improvements in the management of ACS patients
can be achieved in a variety of ways. Evidence exists
that introducing professional education programmes,
care pathways that guide clinical management for com-
mon diseases, and audits against guidelines, all improve
care [8,10]. There is also evidence that financial incen-
tives can lead to improvements in care, which may take
the form of additional payments for achieving pre-
defined targets, or as financial losses for failing to do so
[27]. In addition, if the overall level of health care fund-
ing precludes provision of certain treatments (for exam-
ple under-provision of coronary revascularisation
facilities), this may lead to deficiencies in care that can-
not be improved without an increase in health care
resources for that particular disease area.
There is growing evidence that the provision of sys-
tematic education and training for health professionals
can lead to improvements in standards of care (GAP,
CRUSADE) [8,10]. Several quality improvement pro-
grammes are in progress for ACS patients (GAP, CRU-
SADE, PROMIS-UK, ‘Get-with-the-guidelines’) which
use recent guidelines (ESC, AHA/ACC) as the basis for
the education. The GAP study showed that use of evi-
dence based treatments increased in patients with ST-
elevation MI after an education programme was insti-
tuted. Rates of use of aspirin and beta-blockers in hospi-
tal increased from 81% to 87% (p = 0.02), and 65% to
74% respectively (p = 0.04) after the education pro-
gramme had been delivered. Improved quality of care
has also been shown after education programmes were
instituted in the CRUSADE registry of non-ST elevation
ACS patients. These studies have shown improvements
using historical controls, which has the limitation that
the use of evidence based treatments is often increasing
anyway over time, and this may confound comparisons
between patients enrolled at different times. The GAP
programme, along with other studies, has supported the
hypothesis that the appropriate provision of simple
treatments for ST elevation MI including early thrombo-
lysis, aspirin, beta blockers, statins and ACE Inhibitors
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are surrogate measures for more general indicators of
quality of health care such as organisation of a hospital
and motivation of staff.
Preliminary reports are also available for two recent
controlled studies of education and quality improve-
ment. The QUICC study [28] used a centre-controlled
design to evaluate the efficacy of a quality improvement
programme on 5 health care parameters for ACS
patients: ACE-inhibitors at discharge (for patients with
heart failure or LV dysfunction, diabetes and hyperten-
sion), statins (LDL >3.0 mmol/l, total cholesterol >5.0
mmol/l), clopidogrel (non-ST elevation MI), heparin or
LMWH in-hospital (non ST-elevation MI) and coronary
angiography (non-ST elevation MI with diabetes, prior
MI, ST depression, heart failure). 38 hospitals in Sweden
which were already participating in the RIKS-HIA regis-
try were allocated to a quality improvement (QI) pro-
gramme consisting of seminars and workshops to
highlight ways to improve care, or to a control group
that continued to collect data as before. The RIKS-HIA
registry is an ongoing programme where all acute cen-
tres in Sweden record core information about all ACS
patients using a web-based data collection tool [29,30].
Centres can then interrogate the database to obtain
detailed information about their own patients and com-
pare their performance against group data from the
other participating hospitals. The QUICC study com-
pared the use of the 5 outcome measures prior to the
QI programme and afterwards. There were small
increases in the control centres, except for clopidogrel
which showed a highly significant increase (presumably
because this treatment has recently been approved for
use in ACS), but in the QI centres there were highly sig-
nificant increases in all 5 parameters compared to the
changes in the control centres [28].
The PROMIS-UK study used a cluster-randomised
design in 38 UK centres. Half the centres received an
education programme based on ESC guidelines for the
management of non-ST elevation ACS. The primary
outcome was the use of aspirin, clopidogrel, beta block-
ers and statins at discharge, and heparin in-hospital. A
total of 1028 patients were enrolled. There was an abso-
lute increase in all of the evidence based treatments
between 3.6 to 8.0%. The primary outcome was a com-
posite of all drugs, a score of 1 was allocated for each
drug prescribed and the maximum score was 5. Patients
managed in the control group had a mean score of 4.12
versus 4.36 (adjusted analysis) for patients in the educa-
tion programme group, p = 0.048 [31].
Since application of the results of important clinical
trials and expert clinical guidelines into clinical practice
leads to improved patient care and outcomes, we pro-
pose to test a QI programme based largely on the
Swedish QUICC experience, in a more general group of
hospitals in Europe. If we can demonstrate important
changes in quality of patient care, this may lead to a
greater acceptance that these programmes should be
incorporated into routine training for health profes-
sionals and managers.
Trial hypothesis
The main hypothesis to be tested is that the use of a
structured quality improvement programme will lead to
measurable improvements in the management of care
and use of evidence based treatments for patients pre-
senting to hospital with non-ST elevation acute coron-
ary syndrome.
Aims of project
a) Assess the efficacy and feasibility of a QI programme
for non-ST elevation patients in several European
countries
b) Estimate the costs and potential cost-effectiveness of
the QI strategy
c) Test the feasibility of using the RIKS-HIA data collec-
tion and feedback tool in different European sites and
countries
Methods/study design
This will be a multi-centre cluster-randomised study in
5 European countries: France, Spain, Poland, Italy and
UK.
Selection of centres
EQUIP aims to enrol hospitals representing the full
spectrum of care provided to ACS patients. The empha-
sis however will be on mid-range hospitals that are able
to manage the full range of ACS procedures ideally
including on-site coronary angiography, but those cen-
tres with easy access to coronary angiography at a near-
by hospital will also be included. Sites with on-site car-
diac surgery will be eligible, with a maximum of two
sites permitted per country.
Study phases
The study will be divided into 6 phases as shown in Fig-
ure 1.
Phase 1
Site selection and set-up phase. Potential centres will be
identified by National Co-ordinators and invited to par-
ticipate. 12 centres will be invited assuming a drop-out
rate of 30% leaving on average 8 centres per country.
Thus the expectation is that we will have 40 participat-
ing centres in total. Centres will then be informed about
the study and ethical and regulatory documents
obtained.
All participating centres will be provided with a full
training programme on the EQUIP project and data col-
lection tool using web-based and telephone training
methods.
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Phase 2
Run-in. Centres will enter a run-in phase for one month
to ensure that they are able to collect data properly
using the RIKS-HIA web-based system. An assessment
of data quality and enthusiasm to participate will be
made after this and those centres that are willing and
able to continue will be invited to do so.
Phase 3
Baseline Phase. Centres will be randomised to either QI
programme or control group. Centres will then collect
data for 3 months as part of the baseline assessment of
care.
Phase 4
QI programme (3 months). The main elements of the
QI programme will be delivered over a period of 3
months (see Quality Improvement phase) during
which time all centres will continue to collect data.
Phase 5
Centres will collect data for a further 3 months during
which the QI centres will receive further input and feed-
back on performance.
Phase 6
Data cleaning, study close-out, statistical analyses and
reports
Figure 1 Flow-diagram.
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Patient eligibility
The study aims to enrol patients with a high likelihood
of ACS.
Inclusion criteria
Patients with a good clinical history of ACS and at least
one of the following:
a) New or transient ST or T wave changes on the
ECG consistent with acute myocardial ischaemia
b) Elevation of troponin or other cardiac markers to
levels indicative of myocardial necrosis according to
local laboratory values
Exclusion criteria
• Evidence of persistent ST elevation on the ECG
• Use of early reperfusion therapy (thrombolysis or
primary PCI)
• Patients >80 years
• Patients transferred from another hospital
Very elderly patients have been excluded because
there is existing evidence that in many cases they are
not treated according to guidelines, and thus potential
changes in their treatment patterns may not respond to
a QI programme. We appreciate that this exclusion cri-
terion is pragmatic and other experts will have differing
views on this.
Outcomes
The outcome measures of this study are consistent with
current European guidelines and relate to the manage-
ment and treatment of non-ST elevation ACS patients.
Primary outcome
The primary outcome is a composite of eight outcome
measures to assess aggregate potential for improvement
in care using the QI programme (see statistical section
for further discussion). The outcome measures have
been developed from the new ESC Guidelines for the
diagnosis and treatment of non ST segment elevation
acute coronary syndromes [18]. We have only focused
on selected recommendations with at least Class I and
level of evidence A or B. Text in bold indicates direct
quotes from the ESC Guidelines. The outcome measures
are summarised below:
1. EVIDENCE OF FORMAL DOCUMENTATION OF
RISK STRATIFICATION PERFORMED WITHIN 24
HOURS OF ADMISSION
In Section 4.4 of the ESC guidelines it is stated that:
• Established risk scores (such as GRACE) should
be implemented for initial and subsequent risk
assessment (Recommendation I-B)
The implementation of initial risk stratification meth-
ods will be assessed by this project and this has been
interpreted as occurring within the first 24 hours.
Several methods have been shown to help assess risk
of patients in the early phase of acute coronary syn-
drome. The European Society of Cardiology has recently
adopted the GRACE model [5,18,25] as part of the
European Guidelines and this is the recommended
method of risk stratification. A summary of the GRACE
model is provided in appendix A.
2. EARLY (<72 HRS) CORONARY ANGIOGRAPHY
IN INTERMEDIATE TO HIGH-RISK PATIENTS
In Section 5.4 of the new guidelines:
• Early (<72 h) coronary angiography followed by
revascularisation (PCI or CABG) in patients with
intermediate to high-risk features is recommended
(Recommendation I-A)
Definition of intermediate to high-risk patients
(Section 8.3.3 of the guidelines)
The following features indicate patients who
should undergo routine early angiography:
• Elevated troponin levels
• Dynamic ST or T wave changes (symptomatic or
silent) (≥ 0.5 mm)
• Diabetes mellitus
• Reduced renal function (GFR<60 mL/min/1.73
m2)
• Depressed LVEF<40%
• Early post-MI angina
• PCI within 6 months
• Previous CABG
• Intermediate to high risk according to a risk
score
For the purposes of this project, ECG changes will be
documented as ST-elevation, ST-depression or T wave
inversion. In addition, reduced renal function will be
defined as estimated creatinine clearance<60 ml/min. It
is felt that GFR is not widely established in all hospitals
and that calculation of GFR could be impractical in
some cases leading to missing information.
Documentation of early post-MI angina and whether a
patient has had PCI within 6 months could be difficult
and will be omitted for the purposes of this project.
3. ANTICOAGULATION FOR ALL PATIENTS
Section 5.4 of the guidelines:
• Anticoagulation is recommended for all patients
in addition to antiplatelet therapy (Recommendation
I-A)
• Several anticoagulants are available, namely UFH,
LMWH, fondaparinux, and bivalirudin. The choice
depends on the initial strategy. (Recommendation I-B)
Other more detailed recommendations are provided in
the guidelines but for the sake of simplicity UFH,
LMWH and fondaparinux would be considered suitable
anticoagulants in the early phase of NSTEMI.
4. BETA-BLOCKERS PRESCRIBED AT DISCHARGE
IN PATIENTS WITH REDUCED LV FUNCTION
Section 5.5.7 of the new guidelines:
• Beta-blockers should be given to all patients with
reduced LV function (Recommendation I-A)
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Beta blocker therapy should be initiated in all
patients and maintained indefinitely in the case of
reduced LV function, with or without symptoms of
heart failure, unless formal contraindications exist.
No formal value of LV function is provided by the
guidelines. For the purposes of this project, reduced LV
function has been defined as LVEF ≤ 50%.
5. STATINS PRESCRIBED WITHIN 4 DAYS OF
ADMISSION FOR ALL PATIENTS
In section 5.5.5 of the new guidelines it is stated that
• Statins are recommended for all NSTE-ACS
patients (in the absence of contraindications), irre-
spective of cholesterol levels, initiated early (within
1-4 days) after admission, with the aim of achieving
LDLc levels <100 md/dL (<2.6 mmol/L) (Recommen-
dation I-B)
The second part of this recommendation (achieving
LDLc levels <100 md/dL) is beyond the scope of
EQUIP.
6. ACE-INHIBITORS AT DISCHARGE IN
SELECTED PATIENTS
Section 5.5.8 of the new guidelines:
• ACE inhibitors are indicated long-term in all
patients with LVEF ≤ 40% and in patients with dia-
betes, hypertension, or chronic kidney disease, unless
contraindicated(Recommendation I-A)
ARBs prescribed at discharge if ACE-inhibitors are
contra-indicated.
The definition of chronic kidney disease will be at the
Investigators’ discretion and taken from documentation
in the medical records.
7. CLOPIDOGREL
A) CLOPIDOGREL LOADING DOSE (≥ 300 MG)
ADMINISTERED WITHIN THE FIRST 24 HOURS
FROM ADMISSION
Section 5.3.2 of the new guidelines:
• For all patients, an immediate 300 mg loading
dose of clopidogrel is recommended, followed by a
75 mg clopidogrel daily (Recommendation I-A)
For the purposes of EQUIP, we have interpreted
‘immediate’ as within 24 hours.
B) PRESCRIPTION OF CLOPIDOGREL MAINTE-
NANCE DOSE AT DISCHARGE.
Section 5.3.2 of the new guidelines also recommends:
• Clopidogrel should be maintained for 12 months
unless there is an excessive risk of bleeding. (Recom-
mendation I-A)
The long-term prescription of clopidogrel after dis-
charge is beyond the scope of EQUIP but investigators
will be asked to record whether a maintenance dose (75
mg) has been prescribed at discharge.
Secondary outcomes
a) Clinical outcomes at discharge including death and
myocardial infarction
b) Estimated costs of care for patients
c) Estimated costs and economic evaluation of poten-
tial cost-effectiveness of QI programme
Randomisation
EQUIP-ACS has a cluster-randomised study design.
Randomisation will be stratified by country and abil-
ity to perform percutaneous coronary intervention
on-site. Centres will be randomised to the QI pro-
gramme or not. The co-ordinating centre (CTEU)
will inform centres at the beginning of the baseline
phase of their randomised allocation. The rationale
for this is that personnel at centres allocated to the
QI training programme will require sufficient notifi-
cation to ensure availability and secure travel
arrangements for the meetings. There is a possibility
that knowledge of the randomised allocation may
influence practice patterns. However the influence of
this potential bias can be tested by comparing treat-
ment patterns across the two groups during the base-
line data collection phase.
Quality improvement phase
QI centres
Centres randomised to the QI programme will receive a
“high intensity” quality improvement programme which
will be delivered over a three-month period.
From previous experience, especially in the QUICC
programme [26], the QI programme should encompass
not only guideline driven objectives but also a review
of procedures used by centres to manage patients (e.g.
bed management, early assessment of patients, respon-
sibilities of different health professionals). Thus the QI
programme will have goals and objectives, as well as
emphasising process control. It is suggested that at
least a senior cardiologist, senior nurse and senior
manager attend the QI session from each participating
centre. Every effort will be made to standardise the QI
intervention and this will be achieved by having the
same personnel deliver the programme and for them
to work according to a standard operating procedure.
This will be contained in the study specific quality
improvement manual which will be developed and
approved prior to the start of the QI programme. It is
important that we compare the QI programme centres
to “well managed” control centres. By allowing all cen-
tres (QI and control) to use the specialised data collec-
tion tool developed by Uppsala we anticipate that any
major practice pattern changes will genuinely be the
results of the QI programme and not simply because
centres have easier access to patient data in an electro-
nic format. Thus the control group will receive a “low-
intensity” quality improvement intervention and the QI
group will receive a “high intensity” intervention. We
believe this reflects “optimum” clinical practice and
will allow a fair evaluation of the QI programme.
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The following summarises the main elements of the
QI programme:
Preliminary activities
a) Centre to set up a team (a senior cardiologist, a
junior cardiologist, senior nurse and senior manager)
that have had at least one meeting at their own centre
before session 1.
b) The team should be familiar with the EQUIP proto-
col and contemporary guidelines.
c) The team should be familiar with the registry and
the on-line reports. They should review their baseline
results before session 1.
d) The team should plan weekly meetings (30-60 min-
utes) during the phase 4 (QI Programme) period and
report their work and results continuously on the
EQUIP Internet Portal.
Detailed structure of QI sessions
Session 1 (1 day)
a) Introduction: Why is QI necessary?
b) Short overview of the EQUIP programme
c) Review of the QI programme
d) Goals and methods of measurement
e) Healthcare as a system
f) Identification of potential deficiencies at each centre
g) Centre assignments and contact via Internet portal
Session 2 (1 day)
a) Repetition and reflection
b) Report on centre assignments
c) Improvement ideas
d) How to test new ideas
e) Implementation and requirements for sustained
improvements
f) Homework (test and implement new ideas, internet
portal)
Session 3 (1 day)
a) Repetition and review of activities during QI
programme
b) Report of tests and results
c) Planning of new tests and/or implementation of
successful test
Control group centres
The centres that are randomised to the control group
will receive a “low intensity” programme throughout the
10-month recruitment period. These centres will receive
full training on the EQUIP protocol and database (tele-
phone and internet training as for all centres) in addi-
tion to access to online reports which will enable them
to assess their progress in management of ACS patients.
Regular telephone contact will be maintained with key
staff at these centres to discuss general progress, resolve
any queries and maintain enthusiasm.
Patient enrolment
Daily screening of key wards and admission areas will
identify potentially eligible patients as soon as possible
after admission. All eligible patients will be enrolled into
the study during the 10-month study period. Patients
will be followed up until hospital discharge only to
assess in-hospital treatments and investigations. If a
patient is transferred to another hospital for continuing
care and will be discharged from there, this transfer will
be considered as discharge and staff will be asked to
record the reason for transfer (e.g. patient transferred
for coronary angiography). Centres will be asked to
record data for all eligible patients. Using previous esti-
mates of eligibility and enrolment, we estimate that cen-
tres may enrol 10-15 patients per month which
translates into 4000-5000 patients in total over a 10-
month period. The recruitment period will be approxi-
mately 10 months which includes a one-month run-in
period, baseline phase (3 months), QI training phase (3
months) and QI implementation phase (3 months).
Refer also to Figure 1.
Data collection
Information about eligible patients will be entered onto
the EQUIP-ACS database, which has been adapted from
the RIKS-HIA database to include translations into local
language and some modifications or additions to fields.
The database has a facility to generate online reports
which allows centres to assess their progress. The RIKS-
HIA data collection tool is a validated web-based system
with 10 years of experience [27,28]. All data will be
entered in an anonymous manner at the participating
centres and transferred in an encrypted format to the
main server at UCR, Uppsala where it will be held
securely. All data management will take place at UCR.
Centre training
Before the start of the study, centres will receive training
from CTEU and UCR. Centres will be trained on the
EQUIP data collection tool using a web-based system
and telephone training. The CTEU will provide training
and ensure that centres fully understand the protocol
and procedures of the study.
Ethical and regulatory issues
This study is a QI initiative and therefore can be consid-
ered part of routine professional activity and education.
Except for an increased compliance to accepted stan-
dards and professional guidelines, no change to routine
health care is expected as part of this study. Ethics
Committee Approval has been obtained in each of the 5
countries and for all participating centres for the study
to be conducted without obtaining written informed
consent from patients. Approvals for data to be trans-
ferred from the admission institution to UCR have been
obtained from the appropriate local and national autho-
rities. The study will be conducted in accordance with
Good Clinical Practice guidelines [32] and the Declara-
tion of Helsinki [33]. Permission and support of local
hospital management will be obtained and will be an
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essential part of the success of this programme. Since
this study is not evaluating any specific pharmacological
treatment or medical device it falls outside the European
Clinical Trials Directive and does not require formal
pharmacovigilance.
Sample size and statistical considerations
The primary outcome is based on the 8 quality improve-
ment variables. Two of the variables will be available in
all patients (risk stratification and statin use) whereas
the others will be available in a proportion of the whole
group. We can document the use of treatments as a
proportion at a centre level or at the level of the patient
we can score each variable as 1 (administered) or 0 (not
administered), allowing a maximum score of 8 for each
patient. For the sample size calculation it appeared
more straightforward to use the scoring system. Some
patients will not contribute to the final analysis as they
may not be considered for 5 of the outcome measures.
Using a pragmatic assumption we estimate that the
average “maximum” score per patient will be 5, allowing
for the fact that a proportion will not contribute to the
final analysis. To calculate the sample size we have
taken the possible differences in score using simulated
individual level patient data corrected for centre effect
(i.e. that patterns of practice in a particular centre will
have similarities across patients treated at that centre
and therefore results from each patient cannot be
regarded as “independent”). If the maximum score is
estimated at 5 each one point would equate approxi-
mately to a 20% absolute difference in the frequency of
use of that treatment at a centre level. We estimate that
a 10% absolute difference would be considered reason-
able “minimum” difference to demonstrate that the QI
programme can change practice. This equates to an
absolute average difference of about 0.5 between the QI
centres and control.
In PROMIS-UK [31] we found that a difference of 0.3
between the education group and control group was just
detectable with a p value of 0.05, with a total of 1000
patients and 38 centres. The inter-cluster correlation
coefficient (ICC) for the control arm of PROMIS was
0.10026.
The sample size estimate for EQUIP uses the follow-
ing formula:
N m ICC  Ncluster simple  [ ( )* ]1 1 (1)
Where “Ncluster“ and “Nsimple“ are the sample sizes for
cluster randomisation and simple randomisation respec-
tively. “m” is the number of patients per cluster (i.e. per
hospital) and “ICC” is the inter-cluster correlation
coefficient.
The table below shows the detectable differences in
scores between groups using an ICC of 0.1 or 0.2 and
40 or 50 patients per centre.
Table 1 shows that the study is well powered in the
post QI phase to detect differences of about 0.4 with
800 patients assuming an ICC of 0.2. Our anticipated
total enrolment over the whole period (baseline, during
the QI phase and post QI phase is expected to be a
minimum of 2000 and a maximum of 4000, We believe
the main “power” of the study will lie in the post QI
phase and a total enrolment of 1000 patients (500 per
group) will give us good power to detect differences of
0.3-0.4 which equates to absolute differences in rates of
use of treatments of 6-8%, Since our minimum clinically
important difference is 10%, the study can be considered
“well powered”. Centres will be asked to recruit all non-
ST elevation ACS patients but we do not know the
exact enrolment rate in the centres that will take part
hence the need to identify a range of sample size esti-
mations. However as this is largely driven by the num-
ber of centres it is important we have 40 participating
centres.
It was not felt appropriate to use the estimated differ-
ences between baseline data and post QI data in the
sample size estimation as too many assumptions needed
to be made. Therefore we feel we have made a “conser-
vative” sample size estimation that should allow a good
opportunity to detect realistic differences between the
two groups.
Statistical analysis plan
The primary outcome is a composite of 8 outcome mea-
sures. The proportion of outcomes fulfilled will be cal-
culated on all patients for each time period and group.
The change in the proportion over time (Δ = post QI -
baseline) will be compared between groups.
Analysis of the primary outcome will be by hierarchi-
cal logistic regression to take account of the clustered
nature of the data. For each patient up to 8 binary
Table 1 Sample size calculation based on score of drug
use at discharge
ICC Centres per
Group
Patients per
Centre
Patients per
Group
SD Detectable
Difference
0.1 20 20 400 0.9 0.312
0.1 20 25 500 0.9 0.302
0.1 20 30 600 0.9 0.295
0.1 20 40 800 0.9 0.286
0.1 20 50 1,000 0.9 0.281
0.2 20 20 400 0.9 0.401
0.2 20 25 500 0.9 0.394
0.2 20 30 600 0.9 0.390
0.2 20 40 800 0.9 0.384
0.2 20 50 1,000 0.9 0.380
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quality indicators will be recorded. The quality indica-
tors are therefore nested within patient. Patients, in
turn, are nested within centre. A three-level random
effects model will be fitted with random effects for
patient and centre. An indicator variable for time period
(0 = baseline phase, 1 = post-QI phase) will be entered
at level 2 (patient) as a fixed effect and an indicator vari-
able for treatment group (0 = control, 1 = intervention)
will be entered as a fixed effect at level 3 (centre). Other
centre-level covariates that will be entered as fixed
effects at level 3 are country and ability to perform PCI
on site (since these will be stratification factors in the
randomisation). The interaction between treatment indi-
cator and time period will give a P-value and an esti-
mate of the treatment effect expressed as an odds ratio
for the probability of a quality indicator being fulfilled.
Trial organisation and committees
Study sponsor
The Royal Brompton and Harefield Trust will act as the
Sponsor of this study. The Sponsor’s role is clearly
defined in the ICH Good Clinical Practice guidelines
[32]. Research agreements will be held with the partici-
pating centres.
Steering committee
The Steering Committee (SC) is responsible for main-
taining the scientific integrity and supervising the pro-
gress of the study. The SC will approve the study
protocol and any subsequent amendments. The SC will
meet prior to the start of the study and as required for
the duration of the study.
National co-ordinators
The National Co-ordinators (NCs) will be responsible
for identification of suitable centres in their country and
maintaining contact with these, in addition to liaising
with the central co-ordinating centre (CTEU) and the
data management centre (UCR) to resolve any issues
arising. The NCs will be responsible for obtaining
national regulatory, ethical and local institutional site
approval for the study in addition to ensuring approval
of all subsequent amendments to the study. The NCs
will assist with site training and the QI programme
meetings.
Investigators
It is the responsibility of the Investigator at each partici-
pating site to ensure that approval is obtained from the
appropriate local ethics committee and that a formal
Agreement is signed by the appropriate site signatory.
Investigators will be expected to ensure compliance with
the protocol and all study documentation and to per-
form the study in accordance with Good Clinical Prac-
tice and the Declaration of Helsinki.
The Local Principal Investigators will be required to
identify a research team to assist with the EQUIP study.
Investigators are required to allow access to study docu-
mentation or source data on request for monitoring vis-
its and audits performed by the CTEU or any regulatory
authorities.
Each Investigator and members of the local research
team are responsible for the accuracy, completeness and
legibility of the data entered onto the EQUIP database
and all associated reports. The Investigator must keep a
list containing all patients enrolled into the study. This
patient list remains with the Investigator and is used for
unambiguous identification of each patient. The list con-
tains the patient identification numbers, full names,
dates of birth and dates of enrolment in the study.
These data should identify the trial and should docu-
ment the dates of the patient’s participation.
The Investigator will preserve all records associated
with the study for 10 years or for a period to be deter-
mined by the coordinating centre.
Data management
Uppsala Clinical Research (UCR) will be responsible for
the data collection and management of the study. UCR
will provide the EQUIP database and Internet Portal
and contribute to the QI meetings in addition to assist-
ing with site training.
Study co-ordination
The study will be co-ordinated and managed by the
Clinical Trials and Evaluation Unit (CTEU) at the Royal
Brompton Hospital, London UK. The CTEU will assist
in preparing the final protocol, the investigators’ Manual
of Operations and will assist in training centre staff on
the RIKS-HIA database (telephone and web training) in
addition to participating and assisting in the QI
meetings.
Publication policy and dissemination of results
The results of the study will be submitted for publica-
tion to a peer-reviewed journal irrespective of the out-
come. The Steering Committee will be responsible for
Table 3 Mortality at Six months
Risk
Category
(tertiles)
GRACE Risk
Score
Probability of death post-discharge to
6 months (%)
Low 1-88 <3
Intermediate 89-118 3-8
High 119-263 >8
Table 2 Mortality in hospital
Risk Category
(tertiles)
GRACE Risk
Score
Probability of death in-hospital
(%)
Low 1-108 <1
Intermediate 109-140 1-3
High 141-372 >3
Flather et al. Trials 2010, 11:5
http://www.trialsjournal.com/content/11/1/5
Page 9 of 11
approval of all manuscripts arising from the study prior
to submission for publication. Sub-studies of centre-spe-
cific data may only be carried out with the knowledge
and approval of the Steering Committee.
End of trial
Planned termination
The trial will end when all patients have completed the
observation period, the database has been declared clean
and the main results have been analysed and submitted
for publication.
Discussion
If we can demonstrate important improvements in the
quality of patient care as a result of a quality improve-
ment programme, this could lead to a greater accep-
tance that these programmes should be incorporated
into routine health training for health professionals and
hospital managers.
List of abbreviations used
ACS: Acute Coronary Syndromes; CABG: Coronary
Artery Bypass Grafting; CTEU: Clinical Trials and Eva-
luation Unit; ECG: Electrocardiogram; EQUIP: European
Quality Improvement Programme for Acute Coronary
Syndromes; GFR: Glomerular Filtration rate; ICC: Inter-
cluster Correlation Coefficient; ICH: International Con-
ference on Harmonisation; LVEF: Left Ventricular Ejec-
tion Fraction; LMWH: Low Molecular Weight Heparin;
MI: Myocardial Infarction; NC: National Co-ordinator;
PCI: Percutaneous Coronary Intervention; QI: Quality
Improvement; SC: Steering Committee; UCR: Uppsala
Clinical Research; UFH: Unfractionated heparin.
Appendix A
Summary of GRACE Model
Three risk categories have been developed from the
GRACE risk model and these are summarised in the
Tables 2 and 3 for in-hospital and six-month mortality.
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